High Quality for Artemisinin Powder - Ceftriaxone for inj. – KeMing Medicines Detail:
| FOB Price | Inquiry |
| Min.Order Quantity | 50,000 Vials |
| Supply Ability | 9,000,000 bottles/Month |
| Port | Shanghai |
| Payment Terms | T/T in advance |
| Product Detail | |
| Product name | Ceftriaxone for inj. |
| Specification | 1g+10ml |
| Description | A white, crystalline powder |
| Standard | BP |
| Package | 1Vials+1 ampoule/box |
| Transportation | Ocean,Land,Air |
| Certificate | GMP |
| Price | Inquiry |
| Quality guaranteeperiod | for 36 months |
| Product Description | [Primary indication] Third generation cephalosporin Used for treating neonatal meningitis and sepsis caused by susceptible gram negative organisms(E Coli,Klebsiella,H flu). It competes with bilirubin for binding sites on albumin. |
Product detail pictures:
Related Product Guide:
Medication & Dietary Supplement Interactions – What You Should Know about Drugs and Vitamins
Cholesterol Drugs and Low Vitamin D Along With Other Hormone Levels
Our enterprise since its inception, often regards solution excellent as enterprise life, continually strengthen output technology, enhance product high quality and continually strengthen organization total high-quality administration, in strict accordance using the national standard ISO 9001:2000 for High Quality for Artemisinin Powder - Ceftriaxone for inj. – KeMing Medicines, The product will supply to all over the world, such as: Azerbaijan, Gambia, Slovenia, With more and more Chinese products and solutions around the world, our international business is developing rapidly and economic indicators big increase year by year. We have enough confidence to supply you both better solutions and service, because we've been more and more powerful, specialist and experience in domestic and international.
By Novia from Indonesia - 2018.06.30 17:29
The factory has advanced equipment, experienced staffs and good management level, so product quality had assurance, this cooperation is very relaxed and happy!
By Ellen from South Korea - 2018.08.12 12:27
